The development of economic models and the supporting evidence requires a systematic and methodologically rigorous approach that is aligned with payer coverage requirements and HTA criteria.
- Although many payers and HTA agencies publish methodological guidelines for cost-effectiveness and budget impact modeling, these payer criteria require mapping onto available data to determine the best method on a case-by-case basis.
- Increasingly, reimbursement and HTA agencies are demanding systematic, reproducible synthesis of evidence relating to PROs and costs, as well as efficacy and safety. This evidence is required for all relevant comparators, not just the product for which reimbursement is sought.
- Systematic reviews and indirect/mixed treatment comparisons should be conducted according to published methodological guidelines, which vary country by country.
Planning for evidence generation and synthesis to support economic models must therefore start early in product development to ensure that appropriate data are generated through clinical trials and other supplementary activities, including real-world observational studies.
- The economic models we develop are an integral part of the overall market access strategy, informed by in-depth cross-functional expertise in HTA- and payer-critical issues.
- Our models are built to meet the requirements and expectations of the most demanding payers, while also being adaptable to other markets. We draw on extensive technical expertise and experience at both the industry and payer levels to execute evidence synthesis projects to support HTA submissions and market access strategy.
- Our models and evidence generation strategies are developed in consultation with experts from the key jurisdictions and then rigorously tested through primary research with payers and payer advisors, to ensure that we have anticipated and addressed the likely challenges and are up to date with evolving evidentiary requirements and payer attitudes.